Merck & Co.
As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
Explore Careers In
Our Therapeutic Areas:
We hold ourselves to the highest standards of ethics and integrity.
We’re driven by a desire to improve life
Our values represent the core of our character and guide every decision and action we take.
Patients first
Respect for people
Ethics and integrity
Innovation and scientific excellence
Don’t just join a company … find a sense of belonging! Our Employee Business Resource Groups (EBRGs) are voluntary, employee-led groups that aim to foster a diverse, inclusive work environment by supporting career development while providing culturally relevant insights that drive success. These groups and the people in them will provide a warm welcome to you.
Get to know us personally through employee spotlights, blogs and our podcast! Follow us on careers social for interview tips, resume tips, DEI, divisional information and more!
X | Facebook | Instagram | YouTube | Careers Blog | Career On Purpose Podcast
Blog Post
Sherif Chalifa, Business Analyst for Quality Systems
Sherif Chalifa, Business Analyst for Quality Systems
As I reflect on my time since joining Merck earlier this year, I am thrilled to say that it has been an excellent experience thus far.
Our Business
Our Business
Our Business
Make a change
Make a change
How we hire
How we hire
A decade of oncology advancements
A decade of oncology advancements
NEWS
The FDA approved Merck’s Keytruda for the treatment of stage IB, II or IIIA non-small cell lung cancer after resection or platinum-based chemotherapy.
Merck posted a rare defeat Wednesday for its blockbuster Keytruda (pembrolizumab) in prostate cancer while simultaneously announcing a victory in biliary tract cancer.
The drugmaker’s presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs.
BigHat Biosciences will team up with Merck to design candidates for three drug discovery programs backed by the company’s proprietary AI technology platform.
JOBS
IN THE PRESS